Medical, ethical, and legal aspects of hematopoietic stem cell transplantation for Crohn’s disease in Brazil

Table 2 Demographic and clinical characteristics of Crohn’s disease patients who underwent hematopoietic stem cell transplantation in Beneficencia Portuguesa Hospital SJ Rio Preto (A), São Paulo - Brazil - 2013/2019

Patients, n	50	%
Age, HSCT	32.6 (15-50)
Sex/gender – male/female	22/28	46/54
Time elapsed–symptoms/diagnosis (yr)	6.5 (0-23)
Time elapsed–diagnosis/HSCT (yr)	9.26 (1-28)
Montreal classification
Age diagnosis
A1	14	28.0
A2	35	70.0
A3	1	2.0
Localization	1	2,0
L1	3	6.0
L2	37	74.0
L3	9	18.0
L3 + L4	9	18.0
Behavior	30	60.0
B1	11	22.0
B2
B3
Perianal disease	22	44.0
Extraintestinal diseases	42	84.0
Articular	41	97.6
Skin	8	19.0
Eye	4	9.5
Other	6	14.3
Autoimmune concomitant or previous disease	8	16,0
Fistulas	17	34.0
Anal	12	70,6
Anoretal	4	23.8
Anovaginal	3	17.3
Enteroenteral	4	23.5
Enterovaginal	1	5.9
Enterocutaneous	1	5.9
Other	1	5.9
Ostomia at HSCT	8	16.0
Familial History	10	20.0
Previous surgeries	33	66.0
Previous therapy
Sulfasalazine	39	78.0
Mesalazine	47	94.0
Corticosteroids	50	100
Budesonide	10	20.0
Azathioprine	44	88.0
6-Mercaptopurine	1	2.0
Methotrexate	17	34.0
Cyclosporine	4	8.0
Infliximab	49	98.0
Adalimumab	47	94.0
Certolizumab pegol	4	8.0
Vedolizumab	9	18.0
Ustekinumab	7	14.0
Natalizumab	1	2.0
Etanercept	1	2.0
CDAI	297.8 (155-576.2)
HBi	17.54 (4-48)
CSI	23.16 (10-36)
CDEIS	11.29 (0-36)
SES-CD	14.08 (0-43)

CDAI: Crohn’s Disease Activity Index; HBi: Harvey Bradshaw index.